Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab - Biogen Idec/Genentech

Drug Profile

Rituximab - Biogen Idec/Genentech

Alternative Names: IDEC-102; IDEC-C2B8; IDEC-C2B8-anti-CD20; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec; Cedars-Sinai Medical Center; Chugai Pharmaceutical; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Janssen Research & Development; M. D. Anderson Cancer Center; Mayo Clinic; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Gottingen; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Idiopathic thrombocytopenic purpura; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Pemphigus vulgaris; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase III Mantle-cell lymphoma; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B-cell lymphoma; Glomerulonephritis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Renal transplant rejection
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 05 Feb 2019 Zenyaku Kogyo and Nagoya University Hospital plans the phase II RECIPE trial in Chronic inflammatory demyelinating polyneuropathy (Refractory, In neonates, In infants, In children) in Japan (IV) (UMIN000035753)
  • 31 Jan 2019 Preregistration for Pemphigus vulgaris in European Union (IV), prior to January 2019
  • 31 Jan 2019 Committee for Medicinal Products for Human Use (CHMP) recommends approval of Rituximab for pemphigus vulgaris in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top